# Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

> **NCT00670319** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 7705 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** Raloxifene HCL
- **DRUG:** Raloxifene HCL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00670319
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-11
- **Primary completion:** 1999-09
- **Final completion:** 1999-09
- **Target enrollment:** 7705 (ACTUAL)
- **Last updated:** 2008-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670319, "Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00670319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*